Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
Prescription Drug User Fee Act target action date is February 12, 2027If approved, tinlarebant would be the first-ever







